Clearance mechanism of a mannosylated antibody–enzyme fusion protein used in experimental cancer therapy
The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
MFECP1 is a mannosylated antibody-enzyme fusion protein used in antibody-directed enzyme prodrug therapy (ADEPT). The antibody selectively targets tumor cells and the targeted enzyme converts a prodrug into a toxic drug. MFECP1 is obtained from expression in the yeast Pichia pastoris and produced to clinical grade. The P. pastoris-derived mannosylation of the fusion protein aids rapid normal tissue clearance required for successful ADEPT. The work presented provides evidence that MFECP1 is cleared by the endocytic and phagocytic mannose receptor (MR), which is known to bind to mannose-terminating glycans. MR-transfected fibroblast cells internalize MFECP1 as revealed by flow cytometry and confocal microscopy. Immunofluorescence microscopy shows that in vivo clearance in mice occurs predominantly by MR on liver sinusoidal endothelial cells, although MR is also expressed on adjacent Kupffer cells. In the spleen, MFECP1 is taken up by MR-expressing macrophages residing in the red pulp and not by dendritic cells which are found in the marginal zone and white pulp. Clearance can be inhibited in vivo by the MR inhibitor mannan as shown by increased enzyme activities in blood. The work improves understanding of interactions of MFECP1 with normal tissue, shows that glycosylation can be exploited in the design of recombinant anticancer therapeutics and opens the ways for optimizing pharmacokinetics of mannosylated recombinant therapeutics.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Stahl, P. D., Rodman, J. S., Miller, M. J., & Schlesinger, P. H. (1978) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.75.3.1399 · Cited by 590
Advances in the production of human therapeutic proteins in yeasts and filamentous fungi
Gerngross, T. U. (2004) · Nature Biotechnology · doi:10.1038/nbt1028 · Cited by 409
The mannose receptor: linking homeostasis and immunity through sugar recognition
TAYLOR, P., GORDON, S., & MARTINEZPOMARES, L. (2005) · Trends in Immunology · doi:10.1016/j.it.2004.12.001 · Cited by 368
Linehan, S. A., Martínez-Pomares, L., Stahl, P. D., & Gordon, S. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.189.12.1961 · Cited by 285 · cited 2×
“The macrophage and dendritic cell distributions in the spleen were consistent with other reports where MRexpressing macrophages have been detected in the red pulp and not in the white pulp and marginal zone, whereas dendritic cells localize in the marginal zone and in the white pulp (Linehan et al. 1999).”
ResultRole of the mannose receptor in the immune response
Apostolopoulos, V., & Mckenzie, I. (2001) · Current Molecular Medicine · doi:10.2174/1566524013363645 · Cited by 180
Cited by
Martinez-Pomares, L. (2012) · Journal of Leukocyte Biology · doi:10.1189/jlb.0512231 · Cited by 531
Goetze, A. M., Liu, Y. D., Zhang, Z., Shah, B., Lee, E., Bondarenko, P. V., & Flynn, G. C. (2011) · Glycobiology · doi:10.1093/glycob/cwr027 · Cited by 467
“With another biotherapeutic molecule, rapid clearance of mannosylated antibody–enzyme fusion protein in humans (Kogelberg et al. 2007) was observed, although in this case the enzyme, and not the antibody fragment, contained the high-mannose chains.”
BackgroundMechanisms of ADC Toxicity and Strategies to Increase ADC Tolerability
Nguyen, T. D., Bordeau, B. M., & Balthasar, J. P. (2023) · Cancers · doi:10.3390/cancers15030713 · Cited by 441
Plant‐specific glycosylation patterns in the context of therapeutic protein production
Gomord, V., Fitchette, A., Menu‐Bouaouiche, L., Saint‐Jore‐Dupas, C., Plasson, C., Michaud, D., & Faye, L. (2010) · Plant Biotechnology Journal · doi:10.1111/j.1467-7652.2009.00497.x · Cited by 418
Higel, F., Seidl, A., Sörgel, F., & Friess, W. (2016) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2016.01.005 · Cited by 360
Metadata
- Authors
- Kogelberg, H., Tolner, B., Sharma, S. K., Lowdell, M. W., Qureshi, U., Robson, M., Hillyer, T., Pedley, R. B., Vervecken, W., Contreras, R., Begent, R. H. J., & Chester, K. A.
- Venue
- Glycobiology
- Publisher
- Oxford University Press (OUP)
- Published
- 2006-09-25
- Volume
- 17
- Issue
- 1
- Pages
- 36-45
- ISSN
- 0959-6658 (ISSN-L)
- 1460-2423
- OpenAlex
- W2138223986
- Cited by
- 64
- References
- 5
- FWCI
- 2.02
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Clearance mechanism of a mannosylated antibody–enzyme fusion protein used in experimental cancer therapy. https://app.cochat.ai/papers/10.1093/glycob/cwl053
- The paper
- Kogelberg, H., Tolner, B., Sharma, S. K., Lowdell, M. W., Qureshi, U., Robson, M., Hillyer, T., Pedley, R. B., Vervecken, W., Contreras, R., Begent, R. H. J., & Chester, K. A. (2007). Clearance mechanism of a mannosylated antibody–enzyme fusion protein used in experimental cancer therapy. Glycobiology. https://doi.org/10.1093/glycob/cwl053
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.